As of 4:00pm ET
| -0.15 / -1.15%|
The 2 analysts offering 12-month price forecasts for Melinta Therapeutics, Inc. have a median target of 18.00, with a high estimate of 21.00 and a low estimate of 15.00. The median estimate represents a +40.08% increase from the last price of 12.85.
The current consensus among 2 polled investment analysts is to Buy stock in Melinta Therapeutics, Inc.. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.